Gene2Cure Foundation and Viralgen Announce Collaboration to Advance Rare Disease Gene Therapies
· GlobeWire Daily Business Desk · Source: www.prnewswire.com

Image: Viralgen · Photo source · Resized and letterboxed to 16:9; no AI generation
The Gene2Cure Foundation and Viralgen have announced a collaboration to support the manufacturing of a portfolio of investigational gene therapy programs targeting rare and ultra-rare genetic conditions. According to the announcement issued on November 18, 2026, the partnership combines Gene2Cure's portfolio development capabilities with Viralgen's proprietary Aava™ platform to facilitate efficient clinical advancement.
Collaboration Details and Target Conditions
Under the agreement, Gene2Cure will utilize Viralgen's Aava™ manufacturing platform to advance its pipeline. Initially, the collaboration will support programs focused on:
- PUS3 syndrome
- Smith-Lemli-Opitz syndrome
- GAND
Viralgen will provide adeno-associated virus (AAV) manufacturing services tailored to each program's requirements, including the production of material for toxicological studies and clinical use.
Leadership Perspectives
Professor Leszek Lisowski, co-founder and president of the Gene2Cure Foundation, stated that the collaboration aims to help develop therapies more rapidly and cost-effectively for children suffering from incurable genetic conditions. Jimmy Vanhove, CEO of Viralgen, noted that the partnership supports the advancement of programs through critical pre-clinical and clinical development stages.
Practical Implications and Verification
Stakeholders and interested parties can verify the original announcement and review further organizational details by visiting the official websites at gene2cure.com and viralgen.com, or by consulting official PR Newswire releases. The collaboration represents a step toward addressing unmet medical needs in pediatric rare diseases through contract manufacturing support.
AI-assisted reporting; source claims are attributed and have not been independently verified.



